David E. Johnson
Pfizer
11 Papers
49 Citations
David E. Johnson is an academic researcher from Pfizer. The author has contributed to research in topics: Nicotinic agonist & Agonist. The author has an hindex of 9, co-authored 11 publications.
Chat about Author
Papers
Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects
Karen L. Houseknecht,Alan Robertson,William J. Zavadoski,E. Michael Gibbs,David E. Johnson,Hans Rollema +5 more
TL;DR: OLAN and CLOZ can thus rapidly induce marked insulin resistance, which could contribute to the hyperglycemia and ketoacidosis reported for patients receiving those therapies.
245
Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia.
David E. Johnson,Hanae Yamazaki,Karen M. Ward,Anne W. Schmidt,Wesley S. Lebel,Judith L. Treadway,E. Michael Gibbs,Walter S. Zawalich,Hans Rollema +8 more
TL;DR: It is demonstrated that low concentrations of olanzapine and clozapine can markedly and selectively impair cholinergic-stimulated insulin secretion by blocking muscarinic M3 receptors, which could be one of the contributing factors to their higher risk for producing hyperglycemia and diabetes in humans.
147
Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition.
Hans Rollema,Mihály Hajós,Patricia A. Seymour,Rouba Kozak,Mark J. Majchrzak,Victor Guanowsky,Weldon Horner,Doug S. Chapin,William E. Hoffmann,David E. Johnson,Stafford McLean,Jody Freeman,Kathryn E. Williams +12 more
TL;DR: The preclinical and the limited clinical data show beneficial effects of varenicline, but further clinical studies are needed to evaluate whether the preclinical effects observed in animal models are translatable to the clinic.
120
Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex.
TL;DR: Using microdialysis in rat prefrontal cortex, it is found that 1 mg/kg of the stimulant methylphenidate and the non-stimulant atomoxetine, two widely used treatments for Attention Deficit/Hyperactivity Disorder, produce robust increases in the extracellular levels of histamine, which plays a key role in attention, learning and memory.
58
The 5-hydroxytryptamine4 receptor agonists prucalopride and PRX-03140 increase acetylcholine and histamine levels in the rat prefrontal cortex and the power of stimulated hippocampal θ oscillations.
David E. Johnson,Elena M. Drummond,Sarah Grimwood,Aarti Sawant-Basak,Emily Miller,Elaine E. Tseng,Laura McDowell,Michelle Vanase-Frawley,Katherine Fisher,David M. Rubitski,Kim Jonelle Stutzman-Engwall,Robin T. Nelson,Weldon Horner,Roxanne R Gorczyca,Mihály Hajós,Chester J. Siok +15 more
TL;DR: Findings show for the first time that the 5-HT4 receptor agonists prucalopride and PRX-03140 can increase cortical ACh and histamine levels, augment donepezil-induced ACh increases, and increase stimulated-hippocampal θ power, all neuropharmacological parameters consistent with potential positive effects on cognitive processes.
54